Bioequivalence of Lisdexamfetamine dimesylate 10 mg Capsules in Healthy Participants Under Fasting Conditions.

2024-517732-21-00 Protocol BLCL-LIS-CAN-01 Human pharmacology (Phase I) - Bioequivalence study Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol BLCL-LIS-CAN-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Authorised, recruitment pending
Participants planned 24
Countries 1
Sites 1

No medical condition.

Key facts

Sponsor
Pharmaplot P.C.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Decision date (initial)
2024-12-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No medical condition.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharmaplot P.C.

Sponsor organisation
Pharmaplot P.C.
Address
Kleisthenous And 40a Mouson St
City
Athens
Postcode
153 44
Country
Greece

Scientific contact point

Organisation
Pharmaplot P.C.
Contact name
PharmaPlot PC, Regulatory Affairs Department

Public contact point

Organisation
Pharmaplot P.C.
Contact name
PharmaPlot PC, Regulatory Affairs Department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Authorised, recruitment pending 24 1
Rest of world 0

Investigational sites

Portugal

1 site · Authorised, recruitment pending
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, Rua De Sarmento De Beires 153 0 Floor 3rd Floor, 4250-449, Porto

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-03 Portugal Acceptable
2024-11-13
2024-12-20